314.28 USD
+4.36 (+1.41%)
At close: Jan 29, 2026
313.45 USD
-0.83 (-0.26%)
Pre-Market: 1/30/2026, 9:14:41 AM
Taking everything into account, PRAX scores 3 out of 10 in our fundamental rating. PRAX was compared to 525 industry peers in the Biotechnology industry. While PRAX has a great health rating, there are worries on its profitability. While showing a medium growth rate, PRAX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year PRAX has reported negative net income.
- PRAX had a negative operating cash flow in the past year.
- In the past 5 years PRAX always reported negative net income.
- PRAX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of -68.88%, PRAX is doing worse than 62.10% of the companies in the same industry.
- With a Return On Equity value of -79.49%, PRAX perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.88% | ||
| ROE | -79.49% | ||
| ROIC | N/A |
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- PRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, PRAX has more shares outstanding
- The number of shares outstanding for PRAX has been reduced compared to 5 years ago.
- PRAX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 83.71 indicates that PRAX is not in any danger for bankruptcy at the moment.
- The Altman-Z score of PRAX (83.71) is better than 98.48% of its industry peers.
- There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 83.71 |
ROIC/WACCN/A
WACC8.9%
2.3 Liquidity
- PRAX has a Current Ratio of 5.18. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 5.18, PRAX is in line with its industry, outperforming 57.71% of the companies in the same industry.
- A Quick Ratio of 5.18 indicates that PRAX has no problem at all paying its short term obligations.
- The Quick ratio of PRAX (5.18) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.18 | ||
| Quick Ratio | 5.18 |
3. Growth
3.1 Past
- PRAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.24%.
- Looking at the last year, PRAX shows a very strong growth in Revenue. The Revenue has grown by 364.98%.
EPS 1Y (TTM)-25.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.18%
Revenue 1Y (TTM)364.98%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
- Based on estimates for the next years, PRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 42.06% on average per year.
- PRAX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 314.34% yearly.
EPS Next Y-29.59%
EPS Next 2Y-12.41%
EPS Next 3Y2.55%
EPS Next 5Y42.06%
Revenue Next Year-97.05%
Revenue Next 2Y111.01%
Revenue Next 3Y474.07%
Revenue Next 5Y314.34%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for PRAX. In the last year negative earnings were reported.
- Also next year PRAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.41%
EPS Next 3Y2.55%
5. Dividend
5.1 Amount
- No dividends for PRAX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
PRAXIS PRECISION MEDICINES I / PRAX FAQ
What is the ChartMill fundamental rating of PRAXIS PRECISION MEDICINES I (PRAX) stock?
ChartMill assigns a fundamental rating of 3 / 10 to PRAX.
What is the valuation status of PRAXIS PRECISION MEDICINES I (PRAX) stock?
ChartMill assigns a valuation rating of 0 / 10 to PRAXIS PRECISION MEDICINES I (PRAX). This can be considered as Overvalued.
What is the profitability of PRAX stock?
PRAXIS PRECISION MEDICINES I (PRAX) has a profitability rating of 0 / 10.
Can you provide the expected EPS growth for PRAX stock?
The Earnings per Share (EPS) of PRAXIS PRECISION MEDICINES I (PRAX) is expected to decline by -29.59% in the next year.